08158 CRMI
- 0.320
- 0.0000.00%
CRMI News
CRMI (08158.HK) signed a leasing agreement with Positron.
Grace Covenant, November 1st - China Regenerative Medicine (08158.HK) announced that on November 1, 2024, the company's wholly owned subsidiary HKIRC and CRMI (Hong Kong) (as tenant) entered into a lease agreement with independent third party Zhengxin (as landlord), accordingly, Zhengxin agreed to lease the property to the company.
CRMI: Interim Report 2024
crmi (08158) announced its interim results with a net profit of 16.828 million Hong Kong dollars, a year-on-year increase of 31.86%.
CRMI (08158) announced its mid-term performance for 2024, with earnings of 59.785 million Hong Kong dollars, a year-on-year decrease...
Express News | China Regenerative Medicine International H1 Gross Profit HKD 39.49 Million
Express News | China Regenerative Medicine International H1 Operating Expenses HKD 22.11 Million
Express News | China Regenerative Medicine International H1 Revenue HKD 59.78 Million
CRMI: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
crmi (08158.HK): Zeng Haoxian resigns as a non-executive director.
China Regenerative Medicine (08158.HK) announced on August 21st that Zeng Haoxian has submitted his resignation as a non-executive director due to his intention to devote more time and energy to his other personal businesses, effective from August 20, 2024. After Zeng Haoxian's resignation, he will no longer be a member of the remuneration committee under the board of directors.
CRMI: SUPPLEMENTAL ANNOUNCEMENTIN RELATION TO THE 2023 ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023
CRMI (08158) appointed Huang Baotian as the company secretary and authorized representative.
Zhongguo CRMI (08158) announced that Qiu Huanfa has resigned as the company's corporate secretary and authorized representative. Huang Baotian has been appointed as the company's corporate secretary and authorized representative, effective from July 2, 2024.
CRMI: Annual Report 2023
China Regenerative Medicine (08158.HK): Shareholders' share loss of approximately HK$108 million in 2023
On April 2, China Regenerative Medicine (08158.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$69.49 million, an increase of 67.29% over the previous year; gross profit decreased by 48.37% from the previous year to approximately HK$19.42 million; the company's equity holders should account for the current year's loss of approximately HK$108 million (2022: profit of HK$4.56 million), with a basic loss of HK$37.60 per share.
CRMI: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED 31 DECEMBER 2023
Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 25% Pounding
China Regenerative Medicine appoints Zhongzheng Tianheng as new auditor
China Regenerative Medicine (08158) issued an announcement. On January 25, 2024, Changying (Hong Kong) Certified Public Accountants Limited (Changying) submitted a letter of resignation to the board of directors to resign as the company's auditor, with immediate effect. On January 25, 2024, the board of directors delivered a notice to Changying, stating that after considering the company's cost-benefit factors and the company's failure to reach an agreement with Changying on the audit costs of the Group's comprehensive financial statements (annual review) for the year ended December 31, 2023, the board of directors resolved to recommend that Chang Ying resign as the company's auditor in order to hire another auditor to complete the annual review
China Regenerative Medicine (08158.HK) appoints Zhongzheng Tianheng as new auditor
Gelonghui, January 25 | China Regenerative Medicine (08158.HK) announced that Changying (Hong Kong) Certified Public Accountants Limited (“Changying”) submitted a letter of resignation to the board of directors to resign as the company's auditor with immediate effect. Following the recommendation of the Audit Committee, it has decided to appoint Zhongzheng Tianheng Certified Public Accountants Co., Ltd. (“Zhongzheng Tianheng”) as the company's new auditor.
China Regenerative Medicine (08158) affiliate plans to inject 10.25 million yuan into Changzhou Pomei Biotechnology
Zhitong Finance App News, China Regenerative Medicine (08158) announced that on December 29, 2023 (after the transaction period), China Regenerative Health, Changzhou Starry Sky, and the target company Changzhou Bomei Biotechnology Co., Ltd. signed a capital increase and subscription agreement. According to this, China Regenerative Health must inject RMB 10.25 million into the target company in cash, of which RMB 250,000 will be injected to increase the target company's registered capital, while RMB 10 million will be injected into its capital reserve. Upon completion, the target company will hold approximately 33.3% of China Regenerative Health's equity and Changzhou Star
China Regenerative Medicine International Limited (HKG:8158) Held Back By Insufficient Growth Even After Shares Climb 42%
CRMI: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
CRMI: Third Quarterly Report 2023
Analysis
Price Target
No Data
No Data